surmount-1 tirzepatide non-diabetic obesity weight loss π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Tirzepatide for Weight Loss Without
Pay in 4 interest-free payments of $5.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12






















![Slowpoke (23/108) [Black & White: Dark Explorers] FAB053](https://cdn.shopify.com/s/files/1/0687/6358/2762/products/bc0a3411-d486-4fc0-9116-acd489efa319_0b07f4de-45b9-4906-94d0-c7a1edbe573b.png?v=1696341800)

